共查询到20条相似文献,搜索用时 15 毫秒
1.
Single Brain Metastasis from Thyroid Cancer: Report of Twelve Cases and Review of the Literature 总被引:1,自引:0,他引:1
Salvati M Frati A Rocchi G Masciangelo R Antonaci A Gagliardi FM Delfini R 《Journal of neuro-oncology》2001,51(1):33-40
Brain metastases from thyroid carcinoma is unusual, with a frequency of 1%.We report twelve patients, with single brain metastases and with a karnofsky performance scale score 60 at admission. No metastasis was seen during the uptake of iodine-131, even in the cases from differentiated thyroid carcinoma, suggesting absence of differentiation between primary and metastasic disease. The histopathology of thyroid carcinomas was anaplastic in five cases, differentiated in six, and medullary in one. Only in four patients, brain was the unique site of metastatic spread; in others, bones and lungs were also involved. All metastases were surgically removed, and all patients were treated with radiotherapy (45Gy) in the postoperative course. The survival average was 19.8 months, and the quality of life was satisfactory in all patients. One patient remained alive till 5 years. Anaplastic histopathology and size of the primitive, and also bone involvement of thyroid disease were significant risk factors in our cases (p 0.05). According to the literature, surgery is the best therapeutical choice. Alternative strategies in the management of brain metastasis, such as iodine-131 therapy, are discussed, paying particular attention to the relevant side effects. 相似文献
2.
ZHANG Guo-nan 张国楠 XU Shi-qiang 徐世强 SHI Yu 石宇 FAN ying 樊英 WU Yan-li 吴艳丽 YIN Hong 殷红 YU Jian 余健 CHEN Yi-nan 陈毅男 《中国癌症研究》2002,14(3):230-234
Metastatic spread of cervical carcinoma occurs by local extension and lymphatic dissemination, yet distant metastases do occur in advanced stage. The common sites of distant metastases include liver, lung, and bone. However, brain metastases are uncommon. We had 11 patients with brain metastases from cervical carcinoma in recent decade and retrospectively reviewed these cases to study the mechanisms, diagnosis, treatment, and prognosis. MATERIALS AND METHODS Between January 1990 and… 相似文献
3.
Background
Small cell lung cancer (SCLC) represents approximately 13 to 18% of all lung cancers. It is the most aggressive among lung cancers, mostly presented at an advanced stage, with median survival rates of 10 to12 months in patients treated with standard chemotherapy and radiotherapy. In approximately 15-20% of patients brain metastases are present already at the time of primary diagnosis; however, it is unclear how much it influences the outcome of disease according the other metastatic localisation. The objective of this analysis was to evaluate the median survival of SCLC patients treated by specific therapy (chemotherapy and/or radiotherapy) with regard to the presence or absence of brain metastases at the time of diagnosis.Patients and methods
All SCLC patients have been treated in a routine clinical practice and followed up at the University Clinic Golnik in Slovenia. In the retrospective study the medical files from 2002 to 2007 were review. All patients with cytological or histological confirmed disease and eligible for specific oncological treatment were included in the study. They have been treated according to the guidelines valid at the time. Chemotherapy and regular followed-up were carried out at the University Clinic Golnik and radiotherapy at the Institute of Oncology Ljubljana.Results
We found 251 patients eligible for the study. The median age of them was 65 years, majority were male (67%), smokers or ex-smokers (98%), with performance status 0 to 1 (83%). At the time of diagnosis no metastases were found in 64 patients (25.5%) and metastases outside the brain were presented in 153 (61.0%). Brain metastases, confirmed by a CT scan, were present in 34 patients (13.5%), most of them had also metastases at other localisations. All patients received chemotherapy and all patients with confirmed brain metastases received whole brain irradiation (WBRT). The radiotherapy with radical dose at primary tumour was delivered to 27 patients with limited disease and they got 4–6 cycles of chemotherapy. Median overall survival (OS) of 34 patients with brain metastases was 9 months (95% CI 6–12) while OS of 153 patients with metastases in other locations was 11 months (95% CI 10–12); the difference did not reach the level of significance (p = 0.62). As expected, the OS of patients without metastases at the time of primary diagnosis turned out to be significantly better compared to the survival of patients with either brain or other location metastases at the primary diagnosis (15 months vs 9 and 11 months, respectively, p < 0.001).Conclusions
In our investigated population, the prognosis of patients with extensive SCLS with brain metastases at the primary diagnosis treated with chemotherapy and WBRT was not significantly worse compared to the prognosis of patients with extensive SCLC and metastases outside the brain. In extensive SCLC brain metastases were not a negative prognostic factor per se if the patients were able to be treated appropriately. However, the survival rates of extensive SCLC with or without brain metastases remained poor and novel treatment approaches are needed. The major strength of this study is that it has been done on a population of patients treated in a routine clinical setting. 相似文献4.
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases 总被引:1,自引:0,他引:1
Majer M Jensen RL Shrieve DC Watson GA Wang M Leachman SA Boucher KM Samlowski WE 《Cancer》2007,110(6):1329-1337
BACKGROUND: Brain metastases are an alarming complication of advanced melanoma, frequently contributing to patient demise. The authors performed a retrospective analysis to determine whether the treatment of metastatic melanoma with biochemotherapy would result in similar outcomes if brain metastases were first controlled with aggressive, central nervous system (CNS)-directed treatment. METHODS: Seventy melanoma patients were treated with biochemotherapy for metastatic melanoma between 1999 and 2005. Of these, 20 patients had recently diagnosed brain metastases, whereas 50 did not. Brain metastases (if present) were treated with stereotactic radiosurgery >or=28 days prior to systemic therapy. All patients were treated with biochemotherapy consisting of either dacarbazine or temozolomide in combination with a 96-hour continuous intravenous infusion of interleukin-2 and subcutaneous interferon-alpha-2B. The primary endpoint was survival from the time of the initial diagnosis of metastatic disease. RESULTS: Median survival from the time of the diagnosis of metastatic melanoma was 15.8 months for patients with brain metastases and 11.1 months for those without CNS involvement (P = .26 by the log-rank test; P = .075 by the Gehan Wilcoxon test). Dacarbazine-based and temozolomide-based regimens appeared similar with regard to their effect on overall survival and CNS disease progression. A plateau in further brain recurrences was observed in patients who survived for > 20 months. CONCLUSIONS: Data from the current study suggest that the outcome of biochemotherapy is comparable in patients with and those without brain metastases, if brain metastases are controlled with multidisciplinary treatment. Prolonged survival can be achieved in approximately 15% of patients, regardless of whether or not brain metastases are present. 相似文献
5.
Patients with differentiated thyroid cancer generally have a good prognosis and high cure rates; however, subgroups of patients exist who develop progressive disease with significant morbidity and mortality. We analyzed the clinical outcome of patients with follicular thyroid cancer and distant metastases to define their presentation, impact of therapy and clinical outcome. A group of 44 patients with follicular thyroid cancer which had metastasized to the lungs or the skeleton was identified. All patients were treated at M.D. Anderson Cancer Center between 1965 and 1994. The group included 26 women and 18 men, with a median age of 56 years (range, 23 to 80 years). The primary tumor was limited to the thyroid in most cases. At the time of writing 13 patients were alive with metastatic disease a median of 43 months (range, 4 to 230 months) after diagnosis, while 27 patients died of thyroid cancer a median of 83 months (range, 4 to 238 months) after diagnosis. Bone pain was the chief complaint in almost all the 24 patients in whom distant metastases were present at diagnosis. In the 20 patients who initially presented with localized disease, distant metastases to the skeleton and/or lungs were detected after a median interval of 53 months (range, 8 to 216 months). Symptomatic spinal cord compression occurred in 13 patients and preceded their death by 4 to 34 months. Radioiodine uptake was seen in most bone metastases but in only about half of metastatic foci in the lungs. Radiotherapy was palliative and useful for bone metastases. We conclude that patients with follicular thyroid cancer and distant metastases have a distinct clinical profile that includes prominent skeletal and pulmonary involvement and substantial morbidity and mortality. Intensive multimodality therapy is required to optimize the clinical outcome. 相似文献
6.
Daniel M. Bernad Paul W. Sperduto Luis Souhami Ashley W. Jensen David Roberge 《Journal of neuro-oncology》2010,98(2):249-252
Patients with metastatic well-differentiated thyroid cancer have a generally favorable long-term outcome although multi-organ
involvement is a known marker of poor prognosis. Brain metastases are rare, occurring in less than 1% of patients with thyroid
cancer. Few patients have been managed with stereotactic radiosurgery (SRS). A retrospective database of 5,067 patients treated
for brain metastases between 1985 and 2007 was generated from 11 institutions. Thyroid cancer patients were identified in
this database and, when possible, additional information was obtained from further chart review. Patients were excluded if
they had incomplete treatment or follow-up information. Two validated prognostic indices, Graded prognostic Assessment (GPA)
and Recursive Partitioning Analysis (RPA), were calculated for each patient. The overall survival times were calculated by
the Kaplan–Meier method. Twenty-three thyroid cancer patients were identified (51% male, 48% female). Median age was 63 years
(range 20–81). Pathology of the primary thyroid disease was available for twelve patients; the majority were diagnosed with
differentiated thyroid cancer (n = 9 papillary, n = 2 Hürthle cell; 92%) and one had medullary subtype (8%). Median time from diagnosis of primary disease to brain metastasis
was 41.8 months (range 0–516). Fifteen (65%) patients underwent SRS as part of their initial treatment with a median number
of lesions treated of 1.5 (range 1–9). The median follow-up time for living patients was 35.2 months. Overall median survival
time was 20.8 months (40% alive at last follow-up) and 37.4 months for SRS-treated patients (P = NS). A poor Karnofsky performance status was predictive of worse outcome (P = 0.001). GPA and RPA did not provide additional prognostic information. In conclusion, patients treated with SRS for brain
metastases from primary thyroid cancer have a favorable prognosis with an expected median survival greater than 3 years. It
is unclear as to whether current prognostic indices are relevant to this patient population. 相似文献
7.
Ogawa K Toita T Sueyama H Fuwa N Kakinohana Y Kamata M Adachi G Saito A Yoshii Y Murayama S 《Cancer》2002,94(3):759-764
BACKGROUND: Brain metastases from esophageal carcinoma are extremely rare, and information regarding the natural history, results of treatment, and possible prognostic factors in these patients is limited. METHODS: The records of 36 patients with brain metastases from esophageal carcinoma who were treated between 1986 and 2000 were reviewed. For brain metastases, 12 patients (33%) were treated with surgical resection followed by radiation therapy (S+RT), and the remaining 24 patients were treated with radiation therapy alone. RESULTS: At the initial diagnosis of esophageal carcinoma, the median primary tumor length was 8 cm (range, 2-19 cm), and 26 of 32 available patients (81%) had clinical Stage III-IV tumors according to the International Union Against Cancer 1997 criteria. At time brain metastases appeared, lung metastases were not demonstrated in 25 of 36 patients (69%) who were assessed by chest computed tomography (CT) scans. The overall median survival for all patients was 3.9 months (range, 0.6-36.8 months), and the actuarial survival rates at 12 months and 24 months were 14% and 3%, respectively. In univariate analysis, treatment modality, Karnofsky performance status (KPS), and extracranial disease status each had a statistically significant impact on survival, and, in multivariate analysis, treatment modality and KPS were statistically significant prognostic factors for survival. Five patients (14%) survived more than 1 year, all of whom were treated with S+RT. These five patients had inactive extracranial disease and, four of five patients (80%) had a 90-100% KPS. CONCLUSIONS: Brain metastases from esophageal carcinoma tended to occur in patients with a large primary tumors and/or disease in advanced clinical stages. With the appearance of brain metastases, an absence of lung metastasis frequently was observed on chest CT scans. The prognoses for these patients were generally poor, although selected patients may survive longer with intensive brain tumor treatment. 相似文献
8.
F. Elloumi M. Ben Amor L. Ghorbel H. Mnif T. Boudawara A.M. Ghorbel M. Frikha J. Daoud 《Cancer radiothérapie》2013,17(8):768-770
Metastasis to the central nervous system, either through a hematogenous route or through the cerebrospinal fluid, is extremely rare in nasopharynx cancer. We aim to expose clinical aspects, therapeutic features and prognosis of nasopharyngeal carcinoma with brain metastases. We retrospectively reviewed the medical history of about 420 patients with nasopharyngeal carcinoma treated during 17 years at the university hospital of Sfax (Tunisia). Among them, three patients had brain metastasis. We excluded patients with direct extension to the brain. Tumours of the nasopharynx were locally advanced. The first patient had brain metastases at the initial diagnosis. The two other patients had brain metastases at 10 and 16 months during the follow-up. Ocular signs were the symptoms. Lesions were unique in two patients. Synchronous bone metastases were recorded in the three cases. All patients had whole brain radiation therapy and palliative chemotherapy. All patients had a progression of the disease and died. Brain metastases in nasopharynx cancer represent a rare event. Prognosis is poor, depending on age, surgical excision and synchronous metastases. Survival does not exceed 6 months. 相似文献
9.
About 15% of metastatic breast carcinoma patients are diagnosed with brain metastases. Historically, the majority are treated with palliative external whole-brain radiation with a median survival of 4 months. We examined stereotactic radiosurgery's effect on treatment outcome in such patients. Four hundred and fifty four consecutive patients with brain metastases were treated with stereotactic radiosurgery at Staten Island University Hospital, NY, between 1991 and 1999. The medical records of 60 women with histologically confirmed breast cancer were retrospectively reviewed. Forty-three patients (71%) received fractionated radiosurgery (4×600cGy) and form the core of this report. Sixty five percentage had been previously unsuccessfully treated by whole-brain radiation or had recurrence after craniotomy. Survival was calculated by the Kaplan–Meier method. The median age at diagnosis of brain metastases was 52 years, with median interval of 49 months following the diagnosis of tumor primary. Median survival from brain diagnosis reached 13.6 months. Overall median survival from radiosurgery treatment was 7.5 months. Fifteen patients with one or two brain lesions survived a median of 11.5 months. For the fractionated cohort of patients 1- and 2-year actuarial survival was 28.2% and 12.8%, respectively. Three patients are alive at 32, 34 and 64 months, respectively. We conclude that fractionated radiosurgery improves survival of patients with brain metastases from breast cancer, especially those with small lesions, good functional status and no other metastatic disease. These patients should be encouraged to consider radiosurgery, possibly before WBRT. Considering our 7.5 months overall survival including patients with multiple metastases, and patients with progressive brain metastases despite extensive standard therapy and often systemic disease, these results suggest that radiosurgery could benefit breast cancer patients with brain metastases and extend life. 相似文献
10.
Carolan H Sun AY Bezjak A Yi QL Payne D Kane G Waldron J Leighl N Feld R Burkes R Keshavjee S Shepherd F 《Lung cancer (Amsterdam, Netherlands)》2005,49(1):109-115
OBJECTIVE: The radical treatment of locally advanced non-small cell lung cancer (LA-NSCLC) currently involves combined modality therapy (CMT) with the use of chemotherapy in addition to radiation therapy and/or surgery. Chemotherapy has been shown to improve survival, but does not alter brain relapse. We reviewed the outcomes of Stage IIIA and IIIB LA-NSCLC patients treated with CMT at our institution. We assessed the incidence of brain metastases and the management and outcome of these patients. METHODS: Using our radiation-planning database (RSTS), we identified 230 consecutive patients from the years 1999 and 2000 who received radical radiation therapy to the lung. Extracting data from the chart, we identified 83 patients who were treated radically with chemotherapy, radiation and possibly surgery. These patients form the basis of this study. RESULTS: At 2 years, the actuarial rates for any brain failure, first failure in the brain and sole failure in the brain were 34.2%, 24.6% and 11.0%, respectively. Age was the only factor among sex, histology, stage, weight loss and the timing of chemotherapy and radiation that predicted for an increased risk of first failure in the brain. Patients less than age 60 had a risk of 25.6% versus 11.4% for those greater than 60 (p = 0.022). Among the patients who failed first in the brain, those who had aggressive management of their brain metastases with surgical resection in addition to whole brain radiotherapy had a median survival of 26.3 months compared with 3.3 months for those treated with palliative whole brain radiotherapy alone. CONCLUSION: Brain metastases are common in patients with LA-NSCLC treated with CMT. These patients may benefit from either prophylactic cranial irradiation or early detection and aggressive treatment of brain metastases. 相似文献
11.
S. Campos P. Davey A. Hird B. Pressnail J. Bilbao R.I. Aviv S. Symons F. Pirouzmand E. Sinclair S. Culleton E. DeSa P. Goh E. Chow MBBS 《Current oncology (Toronto, Ont.)》2009,16(1):62-66
Brain metastasis is increasingly common, affecting 20%–40% of cancer patients. After diagnosis, survival is usually limited to months in these patients. Treatment for brain metastasis includes whole-brain radiation therapy, surgical resection, or both. These treatments aim to slow progression of disease and to improve or maintain neurologic function and quality of life.Although less common, primary brain tumours produce symptoms that are similar to those of brain metastasis. Glioblastoma, the most common malignant tumour of the brain, has a median survival of less than 12 months. Patients are often treated with surgical resection followed by radical radiation therapy and chemotherapy.Here, we present 2 separate cases of lesions in the brain radiologically compatible with brain metastasis. In both cases, no primary cancer site had been established, and neurosurgical intervention was sought to obtain a pathologic diagnosis. Both cases were pathologically confirmed as glioblastoma. These cases demonstrate the importance of differentiation between brain metastases and primary brain tumours to ensure that the appropriate management strategy is implemented. 相似文献
12.
BACKGROUND: Brain metastasis is an uncommon, morbid complication of metastatic thyroid carcinoma. Because of its rarity, management often is problematic. To help contribute to the management of this disease entity, the authors present herein what to their knowledge is the largest series reported to date in which all patients had biopsy proven confirmation of their brain metastases. METHODS: The authors report a series of 16 patients with metastatic thyroid carcinoma to the brain who were treated between 1976-2000. The Mayo Clinic database was used to locate and review charts and radiology and pathology reports, and all biopsy specimens were reviewed by one pathologist. The histologic types of carcinoma included 10 papillary carcinomas, 2 follicular carcinomas, 1 Hürthle cell carcinoma, 1 medullary carcinoma, 1 insular carcinoma, and 1 anaplastic carcinoma. Given the small sample size, statistical analyses were not performed. RESULTS: Surgical resection of brain metastases was associated with a trend toward longer survival (20.8 months vs. 2.7 months for no surgical intervention in selected patients) Whole brain external beam radiation therapy produced disease regression in three of the four evaluable patients. Gamma knife radiosurgery and radioactive iodine therapy appear to play limited, but beneficial, therapeutic roles. Overall, survival after the diagnosis of brain metastasis is reported to be longer than that noted with other solid tumors (17.4 months), and the majority of patients die of their extracranial disease (85% in the current series). CONCLUSIONS: The results of the current study indicate that local therapies appear to control brain metastases in the large majority of thyroid carcinoma patients with metastases to the brain. 相似文献
13.
Management of metastatic melanoma patients with brain metastases 总被引:1,自引:0,他引:1
Brain metastases seem to be an almost inevitable complication in patients with metastatic melanoma. Except for the rare patients
who can undergo successful surgical resection of brain metastases, current management strategies do not appear adequate and
result in a poor outcome (median survival, 2–4 months). In recent small series, stereotactic radiosurgery or gamma-knife treatment
has suggested improvement in local control compared with whole brain radiation therapy. We have recently shown prolonged survival
(11.1 months) using a multimodality treatment approach in 44 sequential patients with melanoma brain metastases. A subsequent
study demonstrated that the outcome of biochemotherapy for metastatic melanoma is not affected by the presence or absence
of brain metastases. Our results suggest that the outcome of patients with melanoma brain metastases can be improved using
a multidisciplinary management strategy. 相似文献
14.
D S McMeekin S A Kamelle S A Vasilev T D Tillmanns N S Gould D R Scribner M A Gold S Guruswamy R S Mannel 《Journal of surgical oncology》2001,78(3):194-200; discussion 200-1
PURPOSE: To better define determinants of survival and optimal management strategies for patients with ovarian cancer and brain metastases. METHODS: A review of literature using Medline identified 15 case series of ovarian cancer patients with brain metastases (OBM). Each article was abstracted for survival data, and in all cases, the intervals between ovarian cancer diagnosis and brain metastasis identification, and between brain metastasis identification and last follow-up were recorded. Cases were categorized by patient characteristics and treatment modality for brain metastases. Estimated survival probabilities were plotted using the Kaplan-Meier method with differences between subgroups analyzed by the log-rank test. Cox proportional hazards model was used to identify independent prognostic factors age, number of metastasis, and treatment modality associated with survival. RESULTS: The median interval from ovarian cancer diagnosis to brain metastasis in 104 identified patients was 19.5 months. Brain metastasis was single in 43%, multiple in 41%, and not reported in 16% of cases. About 81.7% of patients were treated for their brain metastases using external radiation therapy (XRT), chemotherapy, and surgery. XRT was utilized in 76% of 104 patients and in 93% of treated patients. The most commonly used modalities were XRT alone (40%) and craniotomy and XRT (17%). The median survival (MS) for all patients regardless of treatment type was 6 months. Patients who received any treatment lived longer than those not receiving surgery/chemotherapy/XRT (MS; 7 months vs. 2 months, P = 0.0001). Patients with single brain metastasis had a longer median survival (21 months vs. 6 months, P = 0.049) when treated with craniotomy plus radiation and/or chemotherapy compared to treatment regimens that excluded craniotomy. In a multivariate analysis, only treatment type was significant in predicting survival. CONCLUSION: OBM portends a poor prognosis, however, long-term survival is possible. Patients appear to benefit from therapy, especially selected groups of OBM patients with single brain metastasis treated with radiation therapy and surgery. 相似文献
15.
Reichardt P Lindner T Pink D Thuss-Patience PC Kretzschmar A Dörken B 《European journal of cancer (Oxford, England : 1990)》2003,39(11):1511-1516
Alveolar soft part sarcoma (ASPS) is a rare tumour. Published series about treatment and outcome are scarce. Conclusive data about the response to chemotherapy are not available. The aim of this study was to analyse the efficacy of palliative chemotherapeutic treatment options and the incidence and mode of presentation of brain metastases. We retrospectively analysed our own sarcoma data-base and reviewed the literature. From our registry containing 757 patients, we identified 8 patients with ASPS. From the literature, 47 cases of adult patients and 13 children with sufficient data about chemotherapy were identified. Response to first-line chemotherapy in 68 patients was: complete remission (CR) 4%, partial remission (PR) 3%, stable disease (SD) 41%, progressive disease (PD) 51%. 285 patients with stage IV disease were evaluable for the analysis of metastatic sites. The incidence of brain metastases was 30.5% (87/285). Brain metastases were detected at a median interval of 48 months (range 0-396 months) after the primary diagnosis. Median survival after the diagnosis of brain metastases was 12 months. The median survival for patients with stage IV disease treated by chemotherapy was 36+ months (range 10-132 months) (31 patients evaluable) with a median follow-up of 46 months (range 10-135 months). ASPS shows a high incidence of brain metastases, at least 3 times higher than that of other soft tissue sarcomas. Chemotherapeutic regimens used for the treatment of other soft tissue sarcomas lack efficacy in ASPS. Staging investigations for ASPS should routinely include imaging of the brain. ASPS patients should not be treated with chemotherapy outside of controlled clinical trials. New targets for specific biologically-directed therapies need to be developed. 相似文献
16.
目的探讨肺癌脑转移患者的临床及影像学特征。
方法回顾性分析2014年1月至2016年12月江苏省肿瘤医院放疗科诊治的228例肺癌脑转移患者的临床资料。
结果228例患者中男性140例,女性88例,中位年龄60岁,腺癌171例,小细胞癌35例,鳞癌22例。有脑转移症状者93例,无症状者135例。中位脑转移瘤确诊时间为5个月,890%患者在2年内确诊脑转移。1年内有、无颅外转移患者的中位脑转移瘤确诊时间分别为30个月和60个月,差异有统计学意义(P<005)。脑实质转移227例,单纯幕上转移149例,单纯幕下转移15例,幕上、幕下均有转移63例。累及幕上者以顶叶(528%)和额叶(448%)最常见。原发灶不同病理类型的脑转移瘤单发及多发病灶分布情况的差异有统计学意义(P<005)。
结论肺癌确诊患者2年内脑转移高发,其中1年内发生其他脏器转移者的脑转移风险更高。肺癌脑转移瘤常多发,转移灶多位于幕上。 相似文献
17.
目的 报道骨肉瘤脑转移患者发生发展的临床特点及其治疗和预后.方法 对我院收治的7例脑转移瘤患者进行回顾分析.结果 本组7例(7/332)骨肉瘤脑转移患者均为儿童及青年,男6例,女1例,中位年龄18岁(9~23岁).单发脑转移瘤6例,多发性脑转移瘤1例.5例脑转移灶位于额叶.骨肉瘤脑转移的常见症状是头痛、恶心和呕吐.2例... 相似文献
18.
In-Young Kim Douglas Kondziolka Ajay Niranjan John C. Flickinger L. Dade Lunsford 《Journal of neuro-oncology》2009,93(3):355-359
Objective We report our experience using gamma knife radiosurgery (GKR) for brain metastasis from thyroid cancer, which is extremely
rare. Methods Between 1995 and 2007, 9 patients with 26 metastatic brain tumor(s) from thyroid cancer underwent GKR. The mean patient age
was 58 years (range: 10–78). Seven patients had metastases from papillary thyroid cancer, and two from medullary thyroid cancer.
Five patients had solitary tumors, and four patients had multiple metastases. Three patients who had multiple metastases also
underwent whole brain radiation therapy (WBRT). The mean tumor volume was 2.4 cc (range: 0.03–14.0). A median margin dose
of 18.0 Gy (range: 12–20) was delivered to the tumor margin. Results Tumor control was obtained in 25 out of 26 tumors (96%). The median progression-free period after GKR was 12 months (range:
4–53). The overall median survival after GKR was 33 months (range: 5–54). There were no procedure-related complications and
six patients are still living 5–54 months after GKR. Conclusions Radiosurgery is an effective and minimally invasive strategy for management of brain metastases form thyroid cancer. 相似文献
19.
Brain metastases from renal carcinoma may appear even a long time after surgical treatment of the primary tumor. The authors present 2 series of patients, one of which has already been published and the other new, for a total of 4 cases of brain metastasis from renal carcinoma with late onset, which occurred 13, 17, 26 and 12 years after primary surgical treatment. The other cases described in the literature were also critically reviewed. 相似文献
20.
《Expert review of anticancer therapy》2013,13(6):879-890
Brain metastases are an attractive target for radiosurgery. Over a period of 6 years, 400 patients with brain metastases have been treated with radiosurgery. Of these patients, 61% had solitary brain metastases and 39% had multiple brain metastases. Local control was achieved in 90% and improvement of severe neurological symptoms in 76%. The median survival time was 8 months. The significant prognostic factors for survival in patients with solitary brain metastases were age, Karnofsky performance status, severity of symptoms, extent of progressive malignant disease outside the brain, histology, interval between diagnosis of primary tumor and brain metastasis, and minimum applied dosage. The significant prognostic factors in patients with multiple brain metastases were sex, Karnofsky performance status and presence of progressive disease outside the brain. 相似文献